CUE vs TT · rev $9.3M vs P/E 36, rev $21.32B
Cue Biopharma (CUE) versus Trane Technologies plc (TT) — a side-by-side from cached financials, not a winner call.
Cue Biopharma (CUE) is a biotechnology company listed on US.
Trane Technologies plc (TT) is a building products & equipment company listed on NYSE.
Latest reported CUE revenue for 2024-12-31 was $9.3M. Net income was -$40.7M. Revenue was up 69.2% from 2023-12-31 to 2024-12-31. CUE currently screens at market cap $59.5M.
Latest reported TT revenue for 2025-12-31 was $21.32B. Net income was $2.92B. Revenue was up 7.5% from 2024-12-31 to 2025-12-31. TT currently screens at market cap $104.45B and trailing P/E 36.2.
CUE currently screens at market cap $59.5M. TT currently screens at market cap $104.45B and trailing P/E 36.2.
Not investment advice. Open the CUE and TT stock pages for the full models.
Not investment advice.